- Home
- FMTO vs ENSC Comparison
FMTO vs ENSC Comparison
Compare FMTO & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMTO
- ENSC
- Stock Information
- Founded
- FMTO 2000
- ENSC 2003
- Country
- FMTO Israel
- ENSC United States
- Employees
- FMTO N/A
- ENSC N/A
- Industry
- FMTO
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- FMTO
- ENSC Health Care
- Exchange
- FMTO NYSE
- ENSC Nasdaq
- Market Cap
- FMTO 3.0M
- ENSC 3.4M
- IPO Year
- FMTO N/A
- ENSC N/A
- Fundamental
- Price
- FMTO $4.60
- ENSC $2.38
- Analyst Decision
- FMTO
- ENSC
- Analyst Count
- FMTO 0
- ENSC 0
- Target Price
- FMTO N/A
- ENSC N/A
- AVG Volume (30 Days)
- FMTO 35.5K
- ENSC 455.1K
- Earning Date
- FMTO 08-06-2025
- ENSC 05-13-2025
- Dividend Yield
- FMTO N/A
- ENSC N/A
- EPS Growth
- FMTO N/A
- ENSC N/A
- EPS
- FMTO N/A
- ENSC N/A
- Revenue
- FMTO $620,978.00
- ENSC $6,224,081.00
- Revenue This Year
- FMTO N/A
- ENSC N/A
- Revenue Next Year
- FMTO N/A
- ENSC $1,381.48
- P/E Ratio
- FMTO N/A
- ENSC N/A
- Revenue Growth
- FMTO N/A
- ENSC 256.35
- 52 Week Low
- FMTO $3.85
- ENSC $1.62
- 52 Week High
- FMTO $6,927.50
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- FMTO N/A
- ENSC 49.99
- Support Level
- FMTO N/A
- ENSC $2.12
- Resistance Level
- FMTO N/A
- ENSC $2.57
- Average True Range (ATR)
- FMTO 0.00
- ENSC 0.21
- MACD
- FMTO 0.00
- ENSC 0.04
- Stochastic Oscillator
- FMTO 0.00
- ENSC 53.87
About FMTO FEMTO TECHNOLOGIES INC
Femto Technologies Inc is an integrated software company. It owns and markets Benefit CRM, a proprietary customer relationship management CRM software product enabling small and medium sized businesses to optimize their day to day business activities such as sales management, personnel management, marketing, call center activities, and asset management.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.